Receive our newsletter – data, insights and analysis delivered to you
  1. News
October 11, 2017

Myeloma UK initiates MUK nine clinical trial for myeloma

Non-profit organisation Myeloma UK has initiated an MUK nine clinical trial that will use genetic techniques to stratify therapy for high-risk myeloma patients in the country.

Non-profit organisation Myeloma UK has initiated an MUK nine clinical trial that will use genetic techniques to stratify therapy for high-risk myeloma patients in the country.

Designed to focus on the sub-group of patients in urgent need for better outcomes, the trial will identify potentially the best treatment for these patients.

The two-part trial will provide access to diagnostics and genetic profiling developed at the Institute of Cancer Research (ICR) in London through research partly funded by Myeloma UK.

The MUK nine A part of the trial will involve screening of 700 newly diagnosed patients at the ICR using genetic analysis of bone marrow samples, and those determined as high risk will be recruited for the MUK nine B part.

The Phase II MUK nine B will evaluate the effectiveness of a combination of bortezomib (Velcade), lenalidomide (Revlimid), daratumumab (Darzalex), dexamethasone and cyclophosphamide administered along with high-dose therapy and stem cell transplantation.

Additionally, the trial will identify disease markers for myeloma to aid the development of stratified medicine for other sub-groups of the disease.

Content from our partners
The importance of reference products in biosimilar trials, and how to source them
Africa’s last mile: Building viable vaccine supply chains
Why this global life sciences COO believes relocation to Charleston, SC, was key to achieving next-level success
“The MUK nine trial will give patients access to innovative new treatments and state-of-the-art molecular testing.”

MUK nine chief investigator and ICR senior researcher Dr Martin Kaiser said: “The MUK nine trial will give patients access to innovative new treatments and state-of-the-art molecular testing.

“We hope it will transform myeloma treatment from a one-size fits all approach to a stratified approach driven by disease characteristics.”

The trial is being planned to be conducted at 30 Clinical Trial Network (CTN) centres across the country and will be co-ordinated and sponsored by the University of Leeds’ Clinical Trials Research unit.

Myeloma UK Research director Dr Simon Ridley said: “This trial is looking to the future – we are trying to gain more insight into which treatment combinations might work best in different groups of patients.

“The data this trial will generate can be used in the UK and beyond to support patient access to the most innovative and effective combination treatments.”

Related Companies

NEWSLETTER Sign up Tick the boxes of the newsletters you would like to receive. Key drug pipeline and competitive landscape changes based on the latest clinical activity, sent every Tuesday. Curated analysis and data-driven insights on clinical trials strategy and operations, sent every Thursday. The pharmaceutical industry's most comprehensive news and information delivered every month.
I consent to GlobalData UK Limited collecting my details provided via this form in accordance with the Privacy Policy
SUBSCRIBED

THANK YOU